{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:50:13Z","timestamp":1761515413738,"version":"build-2065373602"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2006,1,1]],"date-time":"2006-01-01T00:00:00Z","timestamp":1136073600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2006,1,1]],"date-time":"2006-01-01T00:00:00Z","timestamp":1136073600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2006,1]]},"DOI":"10.4158\/ep.12.s1.142","type":"journal-article","created":{"date-parts":[[2013,6,7]],"date-time":"2013-06-07T21:03:16Z","timestamp":1370638996000},"page":"142-147","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"S1","title":["Therapeutic Options in Development for Management of Diabetes: Pharmacologic Agents and New Technologies"],"prefix":"10.1016","volume":"12","author":[{"given":"Harold E.","family":"Lebovitz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.4158\/EP.12.S1.142_bb0005","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.regpep.2004.07.014","article-title":"Glucagon-like peptide 1 and its derivatives in the treatment of diabetes","volume":"128","author":"Nauck","year":"2005","journal-title":"Regul Pept."},{"key":"10.4158\/EP.12.S1.142_bb0010","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1093\/ajhp\/62.2.173","article-title":"Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus","volume":"62","author":"Kolterman","year":"2005","journal-title":"Am J Health Syst Pharm."},{"key":"10.4158\/EP.12.S1.142_bb0015","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.2337\/diacare.28.5.1092","article-title":"Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes","volume":"28","author":"DeFronzo","year":"2005","journal-title":"Diabetes Care."},{"key":"10.4158\/EP.12.S1.142_bb0020","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.2337\/diacare.27.11.2628","article-title":"Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes","volume":"27","author":"Buse","year":"2004","journal-title":"Diabetes Care."},{"key":"10.4158\/EP.12.S1.142_bb0025","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.2337\/diacare.28.5.1083","article-title":"Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea","volume":"28","author":"Kendall","year":"2005","journal-title":"Diabetes Care."},{"key":"10.4158\/EP.12.S1.142_bb0030","series-title":"Program and abstracts of the 65th Scientific Sessions of the American Diabetes Association","article-title":"Comparison of exenatide and insulin glargine in MET and SU-treated patients with type 2 diabetes: exenatide achieved equivalent glycemic control with weight reduction and less nocturnal hypoglycemia","author":"Heine","year":"2005"},{"key":"10.4158\/EP.12.S1.142_bb0035","doi-asserted-by":"crossref","first-page":"2874","DOI":"10.2337\/diacare.27.12.2874","article-title":"Twelve and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes","volume":"27","author":"Ahren","year":"2004","journal-title":"Diabetes Care."},{"key":"10.4158\/EP.12.S1.142_bb0040","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1345\/aph.1C387","article-title":"Pramlintide for the treatment of diabetes mellitus","volume":"37","author":"Kleppinger","year":"2003","journal-title":"Ann Pharmacother."},{"key":"10.4158\/EP.12.S1.142_bb0045","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1007\/s00125-005-1732-4","article-title":"Effect of pramlintide on satiety and food intake in obese subjects and subjects with type 2 diabetes","volume":"48","author":"Chapman","year":"2005","journal-title":"Diabetologia."},{"key":"10.4158\/EP.12.S1.142_bb0050","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1111\/j.1464-5491.2004.01319.x","article-title":"Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in type 1 diabetes mellitus: a 1-year, randomized controlled trial","volume":"21","author":"Ratner","year":"2004","journal-title":"Diabet Med."},{"key":"10.4158\/EP.12.S1.142_bb0055","doi-asserted-by":"crossref","first-page":"3074","DOI":"10.2337\/diacare.26.11.3074","article-title":"Pramlintide reduces postprandial glucose excursions when added to regular insulin or insulin lispro in subjects with type 1 diabetes: a dose-timing study","volume":"26","author":"Weyer","year":"2003","journal-title":"Diabetes Care."},{"key":"10.4158\/EP.12.S1.142_bb0060","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1055\/s-2005-837662","article-title":"Adjunctive therapy with pramlintide lowers HbA1c without concomitant weight gain and increased risk of severe hypoglycemia in patients with type 1 diabetes approaching glycemic targets","volume":"113","author":"Ratner","year":"2005","journal-title":"Exp Clin Endocrinol Diabetes."},{"key":"10.4158\/EP.12.S1.142_bb0065","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1046\/j.1463-1326.2003.00295.x","article-title":"Addition of pramlintide to insulin therapy lowers HbA1c in conjunction with weight loss in patients with type 2 diabetes approaching glycaemic targets","volume":"5","author":"Hollander","year":"2003","journal-title":"Diabetes Obes Metab."},{"key":"10.4158\/EP.12.S1.142_bb0070","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1016\/j.lfs.2005.04.017","article-title":"Rimonabant: the first therapeutically relevant cannabinoid antagonist","volume":"77","author":"Carai","year":"2005","journal-title":"Life Sci."},{"key":"10.4158\/EP.12.S1.142_bb0075","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/S0140-6736(05)66374-X","article-title":"Rissanen AM, Scheen AJ, Ziegler O, Rossner S (RIO-Europe Study Group). Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study","volume":"365","author":"Van Gaal LF","year":"2005","journal-title":"Lancet."},{"year":"2004","series-title":"Effect of rimonabant on weight reduction and weight maintenance: Rimonabant in Obesity-North America (RIO-NA) Trial. Presented at: Annual Meeting of the American Heart Association","author":"Pi-Sunyer","key":"10.4158\/EP.12.S1.142_bb0080"},{"key":"10.4158\/EP.12.S1.142_bb0085","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1021\/jm048993p","article-title":"Discovery of a novel series of peroxisome proliferator-activated receptor alpha\/gamma dual agonists for the treatment of type 2 diabetes and dyslipidemia","volume":"48","author":"Liu","year":"2005","journal-title":"J Med Chem."},{"key":"10.4158\/EP.12.S1.142_bb0090","first-page":"427","article-title":"Muraglitazar (Bristol-Myers Squibb\/Merck)","volume":"6","author":"Barlocco","year":"2005","journal-title":"Curr Opin Investig Drugs."},{"key":"10.4158\/EP.12.S1.142_bb0095","series-title":"Program and abstracts of the 65th Scientific Sessions of the American Diabetes Association","article-title":"Improvement of glycemic control with muraglitazar, a novel dual PPAR alpha\/gamma agonist, in combination with metformin in patients with type 2 diabetes: a double-blind, randomized, pioglitazone-controlled study","author":"Rubin","year":"2005"},{"key":"10.4158\/EP.12.S1.142_bb0100","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1001\/jama.294.20.joc50147","article-title":"Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus","volume":"294","author":"Nissen","year":"2005","journal-title":"JAMA."},{"key":"10.4158\/EP.12.S1.142_bb0105","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1517\/14656566.6.4.643","article-title":"Insulin glulisine: a new rapid-acting insulin analogue for the treatment of diabetes","volume":"6","author":"Garg","year":"2005","journal-title":"Expert Opin Pharmacother."},{"key":"10.4158\/EP.12.S1.142_bb0110","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1111\/j.1464-5491.2005.01545.x","article-title":"Comparison of three multiple injection regimens for type 1 diabetes: morning plus dinner or bedtime administration of insulin detemir vs. morning plus bedtime NPH insulin","volume":"22","author":"Pieber","year":"2005","journal-title":"Diabet Med."},{"key":"10.4158\/EP.12.S1.142_bb0115","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1345\/aph.1E522","article-title":"Inhaled insulin: Exubera","volume":"39","author":"Odegard","year":"2005","journal-title":"Ann Pharmacother."}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X20437656?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X20437656?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/aace.metapress.com\/index\/8K9L555AYQB4TULA.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:46:54Z","timestamp":1761515214000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X20437656"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,1]]},"references-count":23,"alternative-id":["S1530891X20437656"],"URL":"https:\/\/doi.org\/10.4158\/ep.12.s1.142","relation":{},"ISSN":["1530-891X"],"issn-type":[{"type":"print","value":"1530-891X"}],"subject":[],"published":{"date-parts":[[2006,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic Options in Development for Management of Diabetes: Pharmacologic Agents and New Technologies","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.4158\/EP.12.S1.142","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2006 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}